Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

2.

Preamble to the 2015 SITC immunotherapy biomarkers taskforce.

Butterfield LH, Disis ML, Fox BA, Khleif SN, Marincola FM.

J Immunother Cancer. 2015 Mar 24;3:8. doi: 10.1186/s40425-015-0052-6. eCollection 2015.

3.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

4.

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.

Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH.

J Transl Med. 2011 Sep 19;9:155. doi: 10.1186/1479-5876-9-155.

5.

The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.

Butterfield LH.

Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22. Review.

PMID:
28943324
6.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

7.

Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches.

Maciejko L, Smalley M, Goldman A.

J Mol Biomark Diagn. 2017 Sep;8(5). pii: 350. doi: 10.4172/2155-9929.1000350. Epub 2017 Jun 28.

8.

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.

9.

Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM.

J Transl Med. 2010 Dec 7;8:130. doi: 10.1186/1479-5876-8-130.

10.

Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.

Tray N, Weber JS, Adams S.

Cancer Immunol Res. 2018 Oct;6(10):1122-1128. doi: 10.1158/2326-6066.CIR-18-0214.

PMID:
30279188
11.

Immunoengineering with biomaterials for enhanced cancer immunotherapy.

Xie YQ, Wei L, Tang L.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506. doi: 10.1002/wnan.1506. Epub 2018 Jan 14. Review.

PMID:
29333729
12.

Predictive biomarkers for tumor immune checkpoint blockade.

Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H.

Cancer Manag Res. 2018 Oct 11;10:4501-4507. doi: 10.2147/CMAR.S179680. eCollection 2018. Review.

13.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

14.

State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.

Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK.

Eur Urol Focus. 2019 Feb 28. pii: S2405-4569(19)30049-5. doi: 10.1016/j.euf.2019.02.014. [Epub ahead of print] Review.

PMID:
30827939
15.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Pennock GK, Chow LQ.

Oncologist. 2015 Jul;20(7):812-22. doi: 10.1634/theoncologist.2014-0422. Epub 2015 Jun 11. Review.

16.

Basic Overview of Current Immunotherapy Approaches in Cancer.

Velcheti V, Schalper K.

Am Soc Clin Oncol Educ Book. 2016;35:298-308. doi: 10.14694/EDBK_156572. Review.

17.

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J.

Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26589760
18.

Melanoma Immunotherapy: Next-Generation Biomarkers.

Hogan SA, Levesque MP, Cheng PF.

Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018. Review.

19.

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.

Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E; Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers.

J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4. Review.

20.

Prognostic and Predictive Biomarkers in Cancer.

Nair M, Sandhu SS, Sharma AK.

Curr Cancer Drug Targets. 2014;14(5):477-504. Review.

PMID:
24807144

Supplemental Content

Support Center